X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209956
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210275
https://www.prnewswire.com/news-releases/oncopeptides-phase-3-ocean-study-published-in-the-lancet-haematology-301460221.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208392
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213234
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213234
https://www.prnewswire.com/news-releases/halozyme-announces-janssen-submission-of-applications-in-us-and-eu-seeking-approval-of-darzalex-faspro-darzalex-subcutaneous-sc-formulation-utilizing-enhanze-technology-combination-with-pomalidomide-and-dexamethasone-for-pa-301171435.html
https://www.gov.uk/guidance/immunomodulatory-drugs-temporary-pregnancy-prevention-guidance-during-coronavirus-covid-19
https://news.bloomberglaw.com/health-law-and-business/bristol-myers-pomalyst-approved-by-fda-for-kaposi-sarcoma
http://www.pmlive.com/pharma_news/in_virtual_meeting,_chmp_backs_sanofis_myeloma_drug_sarclisa_1330202
https://www.fda.gov/news-events/press-announcements/fda-approves-new-therapy-patients-previously-treated-multiple-myeloma
https://www.gov.uk/government/publications/early-access-to-medicines-scheme-eams-scientific-opinion-isatuximab-in-combination-with-pomalidomide-and-dexamethasone-for-adult-patients
https://endpts.com/darzalex-from-jj-genmab-scores-fda-approval-in-frontline-multiple-myeloma-use-as-sanofi-rival-looms/
https://endpts.com/bristol-myers-abbvies-multiple-myeloma-drug-wins-second-eu-nod-as-part-of-triple-regimen/
https://seekingalpha.com/news/3495058-ec-oks-expanded-label-bristol-myers-empliciti
https://www.fiercepharma.com/pharma/celgene-upbeat-revlimid-pomalyst-myeloma-jumps-as-bristol-myers-merger-nears
https://www.fiercepharma.com/marketing/celgene-s-otezla-heading-for-selloff-nabs-niche-inflammation-market-all-to-itself
https://www.fiercebiotech.com/biotech/fda-accepts-bla-filing-for-sanofi-s-rival-to-j-j-s-darzalex
https://www.fiercepharma.com/marketing/karyopharm-s-xpovio-nabs-multiple-myeloma-nod-despite-checkered-past-but-5th-line?utm_source=internal&utm_medium=rss
https://www.fiercepharma.com/pharma/fda-lifts-partial-hold-venclexta-trial-multiple-myeloma-after-a-spate-deaths
https://www.fiercebiotech.com/biotech/asco-sanofi-s-anti-cd38-combo-boosts-responses-extends-lives-advanced-multiple-myeloma
https://endpts.com/four-years-after-eu-approval-nice-finally-backs-revlimid-use-in-certain-first-line-multiple-myeloma-patients/
http://www.pharmatimes.com/news/revlimid,_imnovid_combos_receive_eu_approval_1288487
https://www.businesswire.com/news/home/20190516005554/en/Celgene-Receives-European-Commission-Approvals-REVLIMID%C2%AE-lenalidomide/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==
https://www.businesswire.com/news/home/20190513005200/en/Celgene-Corporation-Announces-POMALYST%C2%AE-Granted-Breakthrough-Therapy/?feedref=JjAwJuNHiystnCoBq_hl-bQQCakZDujohEJegUyaJwquReQ0P23MrIoWkrUSV24ZevRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxbNWfZlBntHS6jpH5ROLXsTFMkl05DM8ABqeyBleEmzJA==
http://www.pharmatimes.com/news/us_approves_new_use_for_bms_empliciti_1259094
https://www.biospace.com/article/drug-prices-mostly-continue-to-climb-despite-trump-s-promises/
https://seekingalpha.com/article/4194116-6-reasons-celgene-remains-best-valued-large-cap-pharma-stock
https://www.fiercepharma.com/pharma/revlimid-and-pomalyst-price-increases-could-celgene-be-next-trump-s-to-call-list
http://www.pharmatimes.com/news/data_show_imnovid-based_triple_therapy_pfs_benefit_in_blood_cancer_1243316
https://www.fiercepharma.com/celgene-pledges-to-limit-price-hikes-or-does-it
https://www.pharmacompass.com/pdf/news/pomalyst-pomalidomide-capsules-celgene-corporation-v-synthon-1529990446.pdf
https://www.fiercepharma.com/pharma/fda-posts-lists-drugmakers-it-says-may-be-gaming-rules-to-thwart-generic-competition
https://endpts.com/patient-death-forces-fda-to-slap-a-hold-on-early-stage-study-using-combo-from-advaxis-astrazeneca/
https://www.fiercebiotech.com/biotech/after-months-searching-immunomedics-lines-up-celgene-vet-pehl-as-its-new-ceo
http://www.fiercepharma.com/pharma/celgene-takes-its-most-aggressive-price-hikes-revlimid-pomalyst-yet-analyst
https://endpts.com/fda-adds-two-roche-studies-to-its-growing-list-of-partial-clinical-holds-in-wake-of-keytruda-deaths/
http://www.fiercepharma.com/pharma/fda-holds-merck-myeloma-studies-after-keytruda-combos-trigger-trial-deaths
http://www.cetusnews.com/life/FDA-Suspends-Certain-Clinical-Trials-of-Merck%E2%80%99s-Keytruda-.HJeEDQejEb.html
Market Place
Share 
